secwatch / observer

8-K filed September 12, 2024, 7:59 PM ET ticker MCRB CIK 0001609809

other material confidence high sentiment positive materiality 0.75

Seres' SER-155 reduces BSIs 10% vs 42.9% in allo-HSCT Phase 1b; seeks Breakthrough Therapy

Seres Therapeutics, Inc.

SER-155 cut bloodstream infections to 10% vs 42.9% placebo (p=0.0423) in 34 evaluable patients.
Antibiotic exposure duration significantly shorter: 9.2 days vs 21.1 days (p=0.0494).
Febrile neutropenia incidence 65% vs 78.6% (not statistically significant).
No treatment-related serious adverse events; drug strains engrafted in GI tract.
Plans to seek FDA Breakthrough Therapy designation and discuss next steps for allo-HSCT.

item 7.01 item 8.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001193125-24-217627
form_type: 8-K
ticker: MCRB
cik: 0001609809
company_name: Seres Therapeutics, Inc.
filed_at: 2024-09-12T23:59:59+00:00
discovered_at: 2026-05-14T18:03:13.765055+00:00
generated_at: 2026-05-31T05:14:16.257468+00:00
sec_items: ["7.01", "8.01", "9.01"]
event_type: other_material
sentiment: positive
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001193125-24-217627
json_url: https://secwatch.observer/filing/0001193125-24-217627.json
markdown_url: https://secwatch.observer/filing/0001193125-24-217627.md
text_url: https://secwatch.observer/filing/0001193125-24-217627.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1609809/000119312524217627/0001193125-24-217627-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1609809/000119312524217627/d887152d8k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Comparable filings

KRMN

Selling stockholders price upsized secondary offering of 14M shares at $61/share for ~$854M gross proceeds

Karman Holdings Inc. June 1, 2026, 5:28 PM ET other_material Items 1.01, 7.01, 8.01, 9.01

same SEC item: 7.01, 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

CSR

Centerspace approves $240-245M asset sales; exits Bismarck and Rapid City

CENTERSPACE June 1, 2026, 4:30 PM ET other_material Items 7.01, 8.01, 9.01

same SEC item: 7.01, 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

IDYA

IDEAYA's darovasertib combo meets primary endpoint in Phase 2/3 OptimUM-02 trial for metastatic uveal melanoma

IDEAYA Biosciences, Inc. June 1, 2026, 4:05 PM ET other_material Items 7.01, 8.01, 9.01

same SEC item: 7.01, 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

DBX

Dropbox secures $400M revolving credit facility, authorizes $900M share repurchase program

DROPBOX, INC. June 1, 2026, 9:06 AM ET other_material Items 1.01, 2.03, 7.01, 8.01, 9.01

same SEC item: 7.01, 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

NXTC

NextCure Phase 1 SIM0505 data: 55% ORR in gynecologic cancers; cash into Q1 2027

NextCure, Inc. June 1, 2026, 8:10 AM ET other_material Items 7.01, 8.01, 9.01

same SEC item: 7.01, 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

JBIO

Jade Biosciences reports Phase 1 interim data: JADE101 shows ~70% IgA reduction, favorable safety, differentiated PK

Jade Biosciences, Inc. June 1, 2026, 7:55 AM ET other_material Items 7.01, 8.01, 9.01

same SEC item: 7.01, 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

EIKN

Eikon reports 63.1% ORR in Phase 2 NSCLC trial of EIK1001; PARP1 inhibitor EIK1003 shows 24.5% ORR with paclitaxel

Eikon Therapeutics, Inc. June 1, 2026, 7:30 AM ET other_material Items 7.01, 8.01, 9.01

same SEC item: 7.01, 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

TRTX

TRTX posts 1Q26 distributable earnings $0.25/sh, book value $11.06, loan portfolio $4.3B

TPG RE Finance Trust, Inc. June 1, 2026, 5:23 PM ET other_material Items 7.01, 9.01

same SEC item: 7.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

Source: SEC EDGAR

accession 0001193125-24-217627

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.